
    
      The purpose of the present trial is to explore the safety, tolerability and efficacy when
      treating GW with PicatoÂ® 0.05% gel. The primary outcome measures will be related to safety
      and tolerability and consists of severity of any local reactions in the treated area;
      treatment-related adverse events (AEs) and serious AEs.
    
  